Replies to post #9163 on Manhattan Scientifics Inc (MHTX)

[rustydog62]

MAGNETIC MOLECULAR
IMAGING
ONE STEP CLOSER TO THE EARLY
DETECTION OF CANCER
2021 was a very important year for Imagion as we became a
clinical stage company with the commencement of our first-inhuman study of the MagSense® technology for HER2 breast
cancer.
Imagion’s MagSense® technology has the potential to provide
more specific and sensitive detection for cancer than current
imaging technologies. By using tiny magnetic nanoparticles to
identify tumors, our MagSense® technology does not require
use of radioactivity, making it a safer alternative for noninvasive detection.
With a safer, more specific, and more sensitive approach
the Company hopes to enable a new standard of care in the
detection of cancer and other diseases. One that will minimize
the need for biopsies and thereby reducing costs while
minimizing risks for patients.
The current Phase I study of the MagSense® HER2 breast
cancer imaging agent is our first clinical investigation. it is an
important and valuable step forward serving as a proof-ofprinciple that our magnetic molecular imaging technology has
potential to change clinical practices. But it’s just the start.
There are many types of cancer and other diseases that can
benefit from earlier, better, and safer detection.
We’re now one step closer to making a breakthrough in medical
imaging.

Imagion starts 2022 in a strong financial position with our
clinical study well underway and momentum in our research
programs. We are looking forward to bringing our Phase I study
to conclusion and executing our next phase of development.
We are grateful to all our stakeholders - collaborators, patients
that participate in the study, employees, and shareholders - for
their ongoing commitment and support and we look forward to
updating you with progress throughout the year.

On page 22of the Results presentation

"Current Phase 1 study
provides proof-of-concept
that MagSense® imaging is
effective and provides path
to commercialization."

If you're an investor in MHTX, then you're an investor in IBX / IBXXF . Take a victory lap and pat yourself on the back. We've now reached a omni important tipping point. 1/4 four of the annual report for MHTX is due in April, and we can expect to see "Royalty Revenue INCOME" from our Medical Metal Alloy Manufacturer. Hopefully the 1st of a steady stream of quarterly income reports that INCREASE as they progress